PubMed HealthSearch

PubMed · 7594876

A pedigree-based algorithm for finding efficient peeling sequences.

Abstract

The computational cost, in terms of both storage requirements and calculation required, of performing an elimination ordering on a graph is considered as a function of the order in which the vertices of the moral graph are eliminated. Useful properties of the moral graph of a pedigree with respect to vertex elimination are observed and these properties extended to define a k-pedigree as a graph permitting allocation of one of k sexes to each vertex of the graph, such that the subgraph induced by vertices of a single six contains no cycles. Properties of k-pedigrees include an upper bound of 2k on clique size. A novel algorithm, SEXY, based upon these properties is proposed and its performance compared with other algorithms used to generate elimination sequences. It is found to give a widely dispersed range of of sequences, including some sequences requiring under a quarter of the storage and under a half of the computational time than had previously been found using standard methods.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Harbron. 1995. A pedigree-based algorithm for finding efficient peeling sequences.. https://doi.org/10.1093/imammb%2F12.1.13

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels.

Fucosylated glycoproteins carrying alpha1-4 fucose residues are of importance for cell adhesion and as tumor markers. The Lewis gene, FUT3, encodes the only known alpha1-4-fucosyltransferase (FucT), and individuals who are deficient in this enzyme type as Lewis-negative on erythrocytes. We examined the mutational spectrum of the Lewis gene in Denmark and found 6 different mutations. Five, T59G, T202C, C314T, G508A, and T1067A, were frequent, and one, C445A, was only detected in one out of 40 individuals. Allele-specific polymerase chain reaction as well as cloning of FUT3 alleles showed that the 202 and 314 mutations were co-located on the same allele. COS7 cells transfected with an allele having the 202/314 mutations lacked enzyme activity. Polymerase chain reaction-cleavage assays were established for the genotyping of healthy individuals as well as 20 genuine Lewis-negative cancer patients and 10 non-genuine. The latter have Lewis-negative erythrocytes but saliva alpha1-4FucT activity. The genuine Lewis-negative individuals had mutations on both FUT3 alleles. In 66 healthy individuals, a gene dosage effect was detected as FUT3 heterozygous individuals had a lower alpha1-4FucT activity in saliva than did homozygous wild-type individuals. The lower enzyme level in heterozygous individuals resulted in a significantly (p < 0.04) lower level of circulating sialyl-Lewis a structure in serum. This has the clinical impact that cut-off levels in tumor marker assays should be defined on the basis of genotyping. In the group of non-genuine Lewis-negative cancer patients, whose erythrocytes convert from Lewis-positive to Lewis-negative during the disease, FUT3 heterozygosity was significantly (p < 0.05) more common.

ABO Blood-Group System

Bandeiraea (Griffonia) simplicifolia lectin-I, isolectin A4, reacting with Tn (Ga1NAc alpha1 --> Ser/Thr) or galabiose (Ga1 alpha1 --> 4Ga1) containing ligands.

Bandeiraea (Griffonia) simplicifolia lectin-I, isolectin A4(GS I-A4) reacting with the Tn(GalNAc alpha1 --> Ser/Thr) sequence or human blood group Pk active disaccharide (E, Gal alpha1 --> 4Gal, galabiose) was studied by quantitative precipitin (QPA) and precipitin-inhibition assays. When human blood group P1 or Tn active glycoproteins were tested by QPA, GS I-A4 reacted strongly with both the Tn active glycoproteins purified from asialo porcine, ovine and armadillo submandibular glands and a P1 active glycoprotein isolated from sheep hydatid fluid. They precipitated over 80% of the lectin nitrogen added. The asialo porcine salivary glycoprotein-GS I-A4 interaction was inhibited by both Tn containing glycopeptides and Gal alpha1 --> 4Gal indicating that GS I-A4 not only reacts with human blood group A(GalNAc alpha1 --> 3Gal) and B(Gal alpha1 --> 3Gal) active disaccharides, but also recognizes the Tn sequence and the E(Gal alpha1 --> 4-Gal) ligand. From these results, the carbohydrate specificity of GS I-A4 can be defined as A, Tn > or = B and E.

ABO Blood-Group System

Blood-type and age affect human plasma levels of histidine-rich glycoprotein in a large population.

Histidine-rich glycoprotein (HRG) is an alpha2-glycoprotein that was first described by Heimberger, et al, in 1972. Today, HRG is generally regarded as a mild prothrombotic protein. Blood samples of 585 individuals were collected with the aid of the Alameda-Contra Costa Medical Association (ACCMA) Blood Bank, Oakland, CA. Sex, age, ethnic origin, and blood-type information were available for each sample. The blood was processed to isolate the cell free plasma, and plasma HRG concentration was measured relative to that of a normal pool through a modified Laurell technique. Among Caucasian individuals, the mean HRG level of blood-type AB subjects, 125 +/- 28%, was found to be significantly greater than the means for subjects with A and O blood-types, 103 +/- 35% and 105 +/- 30% respectively (P = .0246). In addition, the average HRG level appears to increase linearly with age. The mean plasma level of HRG in subjects 50-59 years old was significantly greater than the level in subjects 30-39 years old (P = .0020). The correlation observed between blood-type and plasma HRG level in this study supports previously reported results that indicate significant genetic control over the plasma level of this protein. The age and blood-type based correlations observed in this study raise the question of whether these variables need be addressed if HRG level were to be employed in a clinical setting as a diagnostic tool.

ABO Blood-Group System